Targeting C-Reactive Protein by Selective Apheresis in Humans: Pros and Cons

• Published in: Journal of clinical medicine Vol. 11; no. 7; p. 1771
• Main Authors: Torzewski, Jan, Brunner, Patrizia, Ries, Wolfgang, Garlichs, Christoph D, Kayser, Stefan, Heigl, Franz, Sheriff, Ahmed
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23.03.2022; MDPI
• Subjects: Adaptive immunity; Antibodies; Apheresis; Autoimmune diseases; Bacterial infections; Cardiomyopathy; Cardiovascular disease; Clinical medicine; Clinical trials; Coronaviruses; COVID-19; Evolution; Heart attacks; Hypotheses; Infections; Myocarditis; Pathogenesis; Pathophysiology; Physiology; Plasma; Proteins; Review; Sepsis; Stroke; Viral infections; COVID-19; arteriosclerosis; therapeutic apheresis; cardiovascular; inflammation; ischemic stroke
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm11071771

C-reactive protein (CRP), the prototype human acute phase protein, may be causally involved in various human diseases. As CRP has appeared much earlier in evolution than antibodies and nonetheless partly utilizes the same biological structures, it is likely that CRP has been the first antibody-like molecule in the evolution of the immune system. Like antibodies, CRP may cause autoimmune reactions in a variety of human pathologies. Consequently, therapeutic targeting of CRP may be of utmost interest in human medicine. Over the past two decades, however, pharmacological targeting of CRP has turned out to be extremely difficult. Currently, the easiest, most effective and clinically safest method to target CRP in humans may be the specific extracorporeal removal of CRP by selective apheresis. The latter has recently shown promising therapeutic effects, especially in acute myocardial infarction and COVID-19 pneumonia. This review summarizes the pros and cons of applying this novel technology to patients suffering from various diseases, with a focus on its use in cardiovascular medicine.